The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

BACKGROUND: The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway are currently in clinical development. It is likely that clinical testing of these agents will be in combination with standard therapies to harness the apoptotic potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Holt, S V, Logié, A, Odedra, R, Heier, A, Heaton, S P, Alferez, D, Davies, B R, Wilkinson, R W, Smith, P D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305954/
https://www.ncbi.nlm.nih.gov/pubmed/22343622
http://dx.doi.org/10.1038/bjc.2012.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305954/
https://www.ncbi.nlm.nih.gov/pubmed/22343622
http://dx.doi.org/10.1038/bjc.2012.8

Ejemplares similares